This article was originally published in The Gray Sheet
Nets $23.1 mil. from public offering of 1.61 mil. shares of common at $15.375, including 210,000 shares sold to underwriters NatWest Securities Limited and Lehman Brothers Inc. under an over-allotment provision. The breast cancer imaging and biopsy systems manufacturer will use the proceeds for "general corporate purposes, including the possible acquisition of one or more businesses," the firm states in a filing with the Securities and Exchange Commission ("The Gray Sheet" March 7, p. 12)
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.